Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: A nationwide population-based cohort study

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 11-12, 2010, Pages 917-923

  Larsen, Mette Vang ^a   Omland, Lars Haukali ^b   Gerstoft, Jan ^b   Røge, Birgit T ^c   Larsen, Carsten Schade ^d   Pedersen, Gitte ^e   Obel, Niels ^b   Kronborg, Gitte ^a  

^a Mental Health Center Glostrup   (Denmark)

^b University of Copenhagen   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG EFFECT; DRUG USE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DENMARK; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78549264508     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2010.511258     Document Type: Article

References (26)

1. Mocroft A, Vella S, Benfi eld TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-30.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodefi ciency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
3. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995 - 2005. Ann Intern Med 2007;146:87-95.
4. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, et al. Causes of death in HIV infection: the key determinant to defi ne the clinical response to anti-HIV therapy. AIDS 2004;18:2333-7.
5. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006;163:412-20.
6. Rodriguez-Arenas MA, Jarrin I, Del Amo J, Iribarren JA, Moreno S, Viciana P, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006;22:715-23.
7. Larsen M, Omland L, Gerstoft J, Larsen C, Jensen J, Obel N, et al. Impact of injecting drug use on mortality in Danish HIV infected patients: a nationwide population based cohort study. Addiction 2009;105:529-35.
8. Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000;14:1829-37.
9. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodefi ciency virus infection. Am J Epidemiol 2005;161:999-1012.
10. Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis 2007;45(Suppl 4):S318 - 23.
11. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
12. Strathdee SA, Palepu A, Cornelisse PG,Y ip B, O S haughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-9.
13. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodefi ciency virus disease. N Engl J Med 1995;333:751-6.
14. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003;169:656-61.
15. Statistics Denmark. Population in Denmark, 1st January 2007. Available at: www.statistikbanken.dk .
16. Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, Pedersen C, et al. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005;37:338-43. (Pubitemid 40691514)
17. Sundhedsstyrelsen. Narkotikasituationen i Danmark 2008. Denmark: National Board of Health. Available at: http://www. s s t . d k / p u b l / P u b l 2 0 0 8 / C F F / N a r k o t i k a /NarkoRapport-08-web.pdf (accessed 1st January 2007).
18. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profi le: the Danish HIV Cohort Study. Int J Epidemiol 2009;38:1202-6.
19. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodefi ciency virus type 1-infected patients. Clin Infect Dis 2002; 35:1541-8.
20. Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B, et al. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Med 2009;10:407-16.
21. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009;338:b1649.
22. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001;15:1707-15. (Pubitemid 32918126)
23. Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005;19:1189-95.
24. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004;350:1850-61.
25. Jorgensen LB, Christensen MB, Gerstoft J, Mathiesen LR, Obel N, Pedersen C, et al. Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scand J Infect Dis 2003;35:800-7.
26. Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006;42:1481-7.